Sign in
CompletedNo phase

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

Key facts

Who runs it
CSL Behring
Where
France11 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
15 people enrolled
Started
18 Oct 2019
Ended
6 May 2024
Type of study
Observational
Record updated
28 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Adult patients (age ≥18 years old)
  • Patients suffering from AATD treated by Respreeza® through a peripheral vein at home for at least 3 month (consecutives or not). The 3-month period of treatment with Respreeza® does not necessarily correspond to the 3 months prior to inclusion
  • Patient accompanied by a third person at home
  • Patients deemed to be suitable by the investigator for self-administration
  • Patients with a life expectancy of over 3 years
  • Patients who have been informed verbally and in writing via the information leaflet and who have signed the informed consent form

Who cannot take part

  • In order to reflect the reality of everyday practice, no non-inclusion criteria are intended except for patient refusal to take part in the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

According to the Respreeza® Summary of Product Characteristics, the initial infusions must be administered under the supervision of a health professional experienced in the treatment of alpha-1 antitrypsin deficiency, although subsequent infusions may be administered at home by the person responsible for care or by the patient.

Read full original descriptionShow less

Clinical data on self-administration of Respreeza® are however limited and the grounds for self-administration are left to the assessment of the attending physician, who needs to ensure that appropriate training is delivered.

In this context, CSL Behring would like to run a clinical study in order to assess the effectiveness of a home self-administration learning program in terms of switching to self-administration, and the long term maintenance of this administration.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Respreeza® Self-administration and Learning Program (AmAREtTI Study- Auto-Administration de Respreeza® et Programme d'apprenTIssage)
Record updated
28 May 2025